Grey-market GLP-1s: the specific risks, and the routes people skip

It usually means semaglutide or tirzepatide bought outside the prescription system — most often powder sold online as a "research peptide" and labelled not for human consumption, sometimes vials shipped from overseas, sometimes product resold person to person. It is not the same thing as compounded medication from a licensed US pharmacy, which is dispensed against a prescription. The defining features here are no prescription, no licensed pharmacy, and no accountable clinician.

You have no way to know, and that is the actual problem. There is no verification of what is in the vial, at what strength, or what else is present. Products sold this way are labelled not for human consumption precisely so the seller is not making a medical claim they would be accountable for. The FDA has documented concerns with unapproved semaglutide products including salt forms — semaglutide sodium and semaglutide acetate — which are not the same as the base semaglutide in approved medicines.

The most documented failure is a dosing error, and the mechanism is mundane rather than exotic. Approved products come in a pen that delivers a set dose. Grey-market product arrives as powder you reconstitute and draw into a syringe yourself, and the instructions circulate in units while the drug is dosed in milligrams. Getting that conversion wrong by a factor of ten is easy and has led to overdoses. Beyond that: unverified strength, sterility with no oversight, no recall mechanism, and no clinician monitoring you for the effects.

These are prescription drugs, and obtaining a prescription medicine without a prescription sits outside the legal supply chain. Importing unapproved drugs is also generally not permitted. We are not your lawyer and this is not legal advice — but the practical point is that the informal market exists precisely because it operates outside the rules that create accountability, which is the same reason nobody is responsible if something goes wrong with your vial.

No, and the distinction matters. Compounded semaglutide or tirzepatide from a licensed US pharmacy is dispensed against a prescription written by a clinician who evaluated you, with a named pharmacy that has a licence to lose. It is still not FDA-approved and its strength and purity are not FDA-verified — a real limitation — but that is a different risk profile from powder bought from an anonymous seller with no clinician and no accountability anywhere in the chain.

Cost, almost always — and frequently after being denied by insurance and concluding that was the end of it. That conclusion is often wrong: a first denial is commonly a documentation problem, such as a missing baseline weight or an undocumented prior therapy, rather than a verdict on eligibility. Patient-assistance programs, which can supply medication at no cost to uninsured income-qualified patients, are also routinely skipped because they require an application.

In order of cost: patient assistance (can be $0 if you qualify), manufacturer self-pay — Zepbound from $299/mo (2.5 mg), Wegovy about $349/month at maintenance, the oral Wegovy pill from around $149 — then the federal TrumpRx portal, then telehealth cash pricing. Each involves a real prescription and a licensed pharmacy. Most people have not worked through all of them before searching for a grey-market source.

The FDA runs BeSafeRx for exactly this, and the NABP maintains a lookup of accredited online pharmacies. The quick signals: a legitimate pharmacy requires a valid prescription, is licensed in your state, has a US-licensed pharmacist available to answer questions, and shows a physical address. Sites that sell without a prescription, offer prices far below every legitimate route, or ship from overseas without one are the ones these tools exist to identify.